Related references
Note: Only part of the references are listed.Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay
Nicola Winstone et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients
Hayley Crawford et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
HLA-Associated Clinical Progression Correlates with Epitope Reversion Rates in Early Human Immunodeficiency Virus Infection
A. Duda et al.
JOURNAL OF VIROLOGY (2009)
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
Jinyan Liu et al.
NATURE (2009)
Adaptation of HIV-1 to human leukocyte antigen class I
Yuka Kawashima et al.
NATURE (2009)
Recombinant vector derived from live attenuated measles virus: Potential for flavivirus vaccines
Samantha Brandler et al.
COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES (2008)
STEP trial and HIV-1 vaccines inducing T-cell responses
Tomas Hanke
EXPERT REVIEW OF VACCINES (2008)
Murine models for HIV vaccination and challenge
Andreas Boberg et al.
EXPERT REVIEW OF VACCINES (2008)
Broad Immunogenicity of a Multigene, Multiclade HIV-1 DNA Vaccine Boosted with Heterologous HIV-1 Recombinant Modified Vaccinia Virus Ankara
Eric Sandstrom et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer
Rodryg Ramlau et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
HLA class I-driven evolution of human immunodeficiency virus type 1 subtype C proteome: Immune escape and viral load
Christine M. Rousseau et al.
JOURNAL OF VIROLOGY (2008)
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
M. Juliana McElrath et al.
LANCET (2008)
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
Susan P. Buchbinder et al.
LANCET (2008)
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans
David I. Watkins et al.
NATURE MEDICINE (2008)
Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads
Morgane Rolland et al.
PLOS ONE (2008)
Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B
Shuangqing Yu et al.
VACCINE (2008)
Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers
A. Guimaraes-Walker et al.
VACCINE (2008)
Safety and immunogenicity of recombinant low-dosage HIV-1 a vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa
Walter Jaoko et al.
VACCINE (2008)
Advances in FIV vaccine technology
Elizabeth W. Uhl et al.
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY (2008)
Genotyping of HLA-I and HLA-II alleles in Chinese patients with paraneoplastic pemphigus
Q. Liu et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Vaccine-induced protection from infection of mice by chimeric human immunodeficiency virus type 1, EcoHIV/NL4-3
Manisha Saini et al.
VACCINE (2007)
Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine
Sven Letourneau et al.
PLOS ONE (2007)
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover
Jorge R. Almeida et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein
Soumitra Roy et al.
VACCINE (2007)
A whole-genome association study of major determinants for host control of HIV-1
Jacques Fellay et al.
SCIENCE (2007)
Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy
Hongbing Yang et al.
JOURNAL OF IMMUNOLOGY (2007)
Preclinical evaluation of candidate HIV type 1 vaccines in inbred strains and an outbred stock of mice
Eung-Jun Im et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2007)
HIV-1-specific CTLs effectively suppress replication of HIV-1 in HIV-1-infected macrophages
Mamoru Fujiwara et al.
BLOOD (2007)
Testing antiretroviral drug efficacy in conventional mice infected with chimeric HIV-1
Eran Hadas et al.
AIDS (2007)
Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy
Lucy Dorrell et al.
VACCINE (2007)
Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes
Isobella Honeyborne et al.
JOURNAL OF VIROLOGY (2007)
Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction
Tomas Hanke et al.
JOURNAL OF GENERAL VIROLOGY (2007)
CD8(+) T-cell responses to different HIV proteins have discordant associations with viral load
Photini Kiepiela et al.
NATURE MEDICINE (2007)
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
Will Fischer et al.
NATURE MEDICINE (2007)
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques
Eung-Jun Im et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2006)
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
Michael R. Betts et al.
BLOOD (2006)
Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine
Lucy Dorrell et al.
JOURNAL OF VIROLOGY (2006)
Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers
I Cebere et al.
VACCINE (2006)
A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness
MJ Potash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence
CL Smith et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Cutting edge: Epitope-dependent effect of Nef-mediated HLA class I down-regulation on ability of HIV-1-specific CTLs to suppress HIV-1 replication
H Tomiyama et al.
JOURNAL OF IMMUNOLOGY (2005)
Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers
JM Vuola et al.
JOURNAL OF IMMUNOLOGY (2005)
Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus
CMC Gutierrez et al.
HUMAN GENE THERAPY (2004)
Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses
JT Snyder et al.
JOURNAL OF VIROLOGY (2004)
Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial
T Matano et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in gambian men
VS Moorthy et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
H McShane et al.
NATURE MEDICINE (2004)
Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults
VS Moorthy et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer
C Rochlitz et al.
JOURNAL OF GENE MEDICINE (2003)
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
SJ McConkey et al.
NATURE MEDICINE (2003)
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry
F Tsamis et al.
JOURNAL OF VIROLOGY (2003)
Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease
CM Rousseau et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population
MJ Estcourt et al.
INTERNATIONAL IMMUNOLOGY (2002)
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
RR Amara et al.
SCIENCE (2001)
Viral load and heterosexual transmission of human immunodeficiency virus type 1
TC Quinn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
